ArticleTherapeutic advances in medical oncology2025
Platelet-to-lymphocyte ratio as a prognostic biomarker in patients with human epidermal growth factor receptor 2-negative breast cancer undergoing taxane-carboplatin-based neoadjuvant chemotherapy.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Taxane-carboplatin-based neoadjuvant chemotherapy (NAC) improves the pathological complete response (pCR) rate in human epidermal growth factor receptor 2 (HER2)-negative breast cancer. However, its effect on long-term survival remains unclear. Reliable prognostic biomarkers are needed to guide personalized postoperative strategies. Objectives: To evaluate the prognostic significance of the platelet-to-lymphocyte ratio (PLR) and to construct a predictive model for overall survival (OS) in this clinical setting. Design: This was a retrospective, multicenter cohort study involving an internal development cohort and an external validation cohort. Methods: We retrospectively analyzed 178 HER2-negative breast cancer patients treated with taxane-carboplatin NAC at Fudan University Shanghai Cancer Center (FUSCC). The optimal PLR cutoff (129.75) was identified via receiver operating characteristic (ROC) analysis. Logistic regression assessed the association between PLR and pCR, and multivariate Cox regression evaluated its prognostic value for OS. A nomogram incorporating PLR, estrogen receptor (ER) status, and clinical stage was built using the FUSCC cohort. The nomogram was externally validated in 34 patients from Fujian Cancer Hospital. Results: Among the 178 patients, 94 (52.8%) had high PLR and 84 (47.2%) had low PLR. High PLR was not independently associated with pCR (odds ratio = 1.006; 95% confidence interval (CI): 0.999-1.013; Conclusion: This is the first study to evaluate PLR as a prognostic marker in HER2-negative breast cancer treated with taxane-carboplatin NAC. High PLR was independently associated with poorer survival. The proposed nomogram provides a practical tool for postoperative risk stratification and personalized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.